{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:07:32Z","timestamp":1790485652002,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","geriatric.theclinics.com","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Geriatric Medicine"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.cger.2015.08.012","type":"journal-article","created":{"date-parts":[[2015,10,21]],"date-time":"2015-10-21T06:08:40Z","timestamp":1445407720000},"page":"191-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults"],"prefix":"10.1016","volume":"32","author":[{"given":"Emily J.","family":"Guerard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha A.","family":"Tuchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.cger.2015.08.012_bib1","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cger.2015.08.012_bib2","unstructured":"Institute NC. SEER stat fact sheets: myeloma. 2015. Available at: http:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed May 18, 2015."},{"issue":"1","key":"10.1016\/j.cger.2015.08.012_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"25","key":"10.1016\/j.cger.2015.08.012_bib4","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cger.2015.08.012_bib5","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","article-title":"Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States","volume":"107","author":"Landgren","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cger.2015.08.012_bib6","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.cger.2015.08.012_bib7","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A\u00a0monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.cger.2015.08.012_bib8","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.cger.2015.08.012_bib9","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1158\/1078-0432.CCR-09-1575","article-title":"Prevention of progression in monoclonal gammopathy of undetermined significance","volume":"15","author":"Rajkumar","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.cger.2015.08.012_bib10","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.cger.2015.08.012_bib11","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1182\/blood-2008-05-159665","article-title":"Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors","volume":"113","author":"Iwanaga","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cger.2015.08.012_bib12","first-page":"251","article-title":"Farming and mortality from multiple myeloma: a case-control study with the use of death certificates","volume":"72","author":"Cantor","year":"1984","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.cger.2015.08.012_bib13","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2013.100552","article-title":"The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network","volume":"99","author":"van de Donk","year":"2014","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.cger.2015.08.012_bib14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1532-5415.1993.tb02054.x","article-title":"Interleukin-6: a cytokine for gerontologists","volume":"41","author":"Ershler","year":"1993","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"12","key":"10.1016\/j.cger.2015.08.012_bib15","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood.V96.12.3880","article-title":"The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells","volume":"96","author":"Rawstron","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cger.2015.08.012_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"10.1016\/j.cger.2015.08.012_bib17","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood-2004-05-1812","article-title":"Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia","volume":"104","author":"Guralnik","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cger.2015.08.012_bib18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2141.2010.08207.x","article-title":"Monoclonal gammopathy of undetermined significance: a consensus statement","volume":"150","author":"Berenson","year":"2010","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.cger.2015.08.012_bib19","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A\u00a0long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.cger.2015.08.012_bib20","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.cger.2015.08.012_bib21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.cger.2015.08.012_bib22","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cger.2015.08.012_bib23","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1200\/JCO.20.6.1625","article-title":"Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"20","author":"Cesana","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.cger.2015.08.012_bib24","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood-2010-04-277566","article-title":"Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications","volume":"116","author":"Bianchi","year":"2010","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.cger.2015.08.012_bib25","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.cger.2015.08.012_bib26","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.cger.2015.08.012_bib27","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A\u00a0clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.cger.2015.08.012_bib28","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/leu.2009.61","article-title":"Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant","volume":"23","author":"Hari","year":"2009","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.cger.2015.08.012_bib29","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.cger.2015.08.012_bib30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.cger.2015.08.012_bib31","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.cger.2015.08.012_bib32","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1634\/theoncologist.2011-0229","article-title":"Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data","volume":"16","author":"Pulte","year":"2011","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.cger.2015.08.012_bib33","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cger.2015.08.012_bib34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1046\/j.1365-2141.2001.03043.x","article-title":"Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia","volume":"115","author":"Wahlin","year":"2001","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.cger.2015.08.012_bib35","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1200\/JCO.2012.46.2598","article-title":"Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the Intergroupe Francophone du My\u00e9lome experience","volume":"31","author":"Avet-Loiseau","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.cger.2015.08.012_bib36","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood-2007-03-081018","article-title":"Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group","volume":"111","author":"Ludwig","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cger.2015.08.012_bib37","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/ajh.21191","article-title":"Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis","volume":"83","author":"Kumar","year":"2008","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.cger.2015.08.012_bib38","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1200\/JCO.1996.14.4.1327","article-title":"Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant","volume":"14","author":"Miller","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.cger.2015.08.012_bib39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3109\/10428194.2011.606942","article-title":"Feasibility of autologous hematopoietic stem cell transplant in patients aged \u226570 years with multiple myeloma","volume":"53","author":"Bashir","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.cger.2015.08.012_bib40","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/cncr.21422","article-title":"Developing a cancer-specific geriatric assessment: a feasibility study","volume":"104","author":"Hurria","year":"2005","journal-title":"Cancer"},{"issue":"25","key":"10.1016\/j.cger.2015.08.012_bib41","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.cger.2015.08.012_bib42","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/cncr.26646","article-title":"Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score","volume":"118","author":"Extermann","year":"2012","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.cger.2015.08.012_bib43","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.cger.2015.08.012_bib44","doi-asserted-by":"crossref","unstructured":"Wildes T, Tuchman SA. Geriatric assessment (GA) and eligibility for autologous stem cell transplant (ASCT) in older adults with newly diagnosed multiple myeloma (MM). Paper presented at: Journal of Clinical Oncology. Chicago, IL, 2015.","DOI":"10.1200\/jco.2015.33.15_suppl.e20525"},{"issue":"13","key":"10.1016\/j.cger.2015.08.012_bib45","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.cger.2015.08.012_bib46","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A\u00a0phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.cger.2015.08.012_bib47","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cger.2015.08.012_bib48","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.cger.2015.08.012_bib49","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","article-title":"Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline","volume":"144","author":"Richardson","year":"2009","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.cger.2015.08.012_bib50","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1182\/blood-2009-08-239046","article-title":"Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients","volume":"115","author":"Gay","year":"2010","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.cger.2015.08.012_bib51","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.cger.2015.08.012_bib52","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.cger.2015.08.012_bib53","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2012-09-452375","article-title":"Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02","volume":"121","author":"Leleu","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cger.2015.08.012_bib54","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.cger.2015.08.012_bib55","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1200\/JCO.2014.55.1028","article-title":"Multiple myeloma in the older adult: better prospects, more challenges","volume":"32","author":"Wildes","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.cger.2015.08.012_bib56","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cger.2015.08.012_bib57","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(11)70157-7","article-title":"Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial","volume":"12","author":"Morgan","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.cger.2015.08.012_bib58","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"issue":"1","key":"10.1016\/j.cger.2015.08.012_bib59","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.nutres.2010.12.001","article-title":"Prevalence and correlates of vitamin D deficiency in US adults","volume":"31","author":"Forrest","year":"2011","journal-title":"Nutr Res"},{"issue":"1","key":"10.1016\/j.cger.2015.08.012_bib60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00520-009-0793-1","article-title":"Living with multiple myeloma: experiences of patients and their informal caregivers","volume":"19","author":"Molassiotis","year":"2011","journal-title":"Support Care Cancer"}],"container-title":["Clinics in Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069015000804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069015000804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T22:22:41Z","timestamp":1718144561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749069015000804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0749069015000804"],"URL":"https:\/\/doi.org\/10.1016\/j.cger.2015.08.012","relation":{},"ISSN":["0749-0690"],"issn-type":[{"value":"0749-0690","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults","name":"articletitle","label":"Article Title"},{"value":"Clinics in Geriatric Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cger.2015.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}